Frequency of Hyperprolactinemia in Infertile (Primary and Secondary) Women Presenting at OPD of Gyneacology

. Moomal; Shahida  Shaikh

doi:10.54112/bcsrj.v6i6.2059

Authors

. Moomal Department of Obstetrics and Gynaecology Unit-1, Shaikh Zaid Women Hospital Larkana Shaheed Mohtrama Benazir Bhutto Medical University, Larkana, Pakistan
Shahida Shaikh Department of Obstetrics and Gynaecology Unit-1, Shaheed Mohtrama Benazir Bhutto Medical University, Larkana, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v6i6.2059

Keywords:

Hyperprolactinemia, Infertility Female, Infertility Primary, Infertility Secondary, Prolactin

Abstract

Background: Infertility is a major reproductive health concern affecting up to 15% of couples globally. Among its multiple etiologies, endocrine abnormalities, particularly hyperprolactinemia, are recognized as frequent yet treatable causes of anovulation and menstrual irregularities. Objective: To determine the frequency of hyperprolactinemia among infertile women presenting to the gynecology outpatient department and to compare its occurrence between primary and secondary infertility. Methodology: This cross-sectional descriptive study was conducted at Shaikh Zaid women hospital Larkana from August 2023 to Jan 2024. A total of 135 infertile women aged 18–45 years were included using non-probability consecutive sampling. Women with thyroid or pituitary disorders, chronic illnesses, or recent use of dopamine-modulating drugs were excluded. After informed consent, demographic and clinical data were recorded, and fasting serum prolactin levels were measured using a chemiluminescent immunoassay. Results: The mean age of participants was 29.7 ± 5.1 years. Primary infertility was observed in 82 (60.7%) and secondary infertility in 53 (39.3%) women. Hyperprolactinemia was detected in 46 participants, yielding a frequency of 34.1%. The condition was significantly more prevalent in women with primary infertility (43.9%) compared to secondary infertility (18.9%) (p = 0.002). Mean serum prolactin levels were 32.4 ± 17.9 ng/mL in primary infertility and 20.6 ± 10.8 ng/mL in secondary infertility. Menstrual irregularities (95.6%) and galactorrhea (28.2%) were significantly more common among hyperprolactinemic women (p < 0.05). No significant association was found with age or BMI. Conclusion: Hyperprolactinemia is a prevalent and reversible cause of infertility, particularly among women with primary infertility.

Downloads

Download data is not yet available.

References

Badesara S, Jakhar K. A cross sectional study to find the prevalence of hyperprolactinemia in infertile euthyroid patients in a hospital. Int J Reprod Contracept Obstet Gynecol 2020;9:4394-7.

Shu J, Xing L, Zhang L, et al. Ignored adult primary hypothyroidism presenting chiefly with persistent ovarian cysts: a need for increased awareness. Reprod Biol Endocrinol. 2011;9(1):119.

Goswami B, Patel S, Chatterjee M, Koner BC, Saxena A. Correlation of prolactin and thyroid hormone concentration with menstrual patterns in infertile women. J Reprod Infertil. 2009;10(3):207–12.

Oyebanji OG, Asaolu MF, Amonimo EO. Hormonal imbalance in polycystic ovarian syndrome (PCOS) in teaching hospitals in Ekiti State, Nigeria. Open J Obstet Gynecol. 2018;8(13):1456–64.

Turankar S, Sonone K, Turankar A. Hyperprolactinaemia and its comparison with hypothyroidism in primary infertile women. J Clin Diagn Res. 2013;7(5):794–6.

Nallusamy S, Gracelyn LJ. Prevalence of hyperprolactinemia in infertile women and its association with hypothyroidism. Int J Adv Med. 2016;3(1):33–8.

Davis LB, Lathi RB, Dahan MH. The effect of infertility medication on thyroid function in hypothyroid women who conceive. Thyroid. 2007;17:773–7.

Poppe K, Velkenier B, Glinoer D. Thyroid disease and female reproduction. Clin Endocrinol (Oxf). 2007;66:309–21.

Goyal A, Ganie MA. Idiopathic hyperprolactinemia presenting as polycystic ovary syndrome in identical twin sisters: a case report and literature review. Cureus. 2018;10(7):e3004.

Nupur H, Andaleeb F, Premlata M, Nisha S, Swati G, Sapna A, Avantika S, Nidhi S. Correlation of prolactin and thyroid hormone levels in infertile women. Sch Acad J Biosci. 2015;3(1A):1–2.

Nallusamy S, Gracelyn LJ. Prevalence of hyperprolactinemia in infertile women and its association with hypothyroidism. Int J Adv Med. 2016;3:33–8.

Singh S, Pal N, Shubham S, Sarma DK, Verma V, Marotta F, et al. Polycystic ovary syndrome: etiology, current management, and future therapeutics. J Clin Med. 2023;12:1454.

Joham AE, Norman RJ, Stener-Victorin E, Legro RS, Franks S, Moran LJ, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022;10:668–80.

Delcour C, Robin G, Young J, Dewailly D. PCOS and hyperprolactinemia: what do we know in 2019? Clin Med Insights Reprod Health. 2019;13:1–7.

Al-Chalabi M, Bass AN, Alsalman I. Physiology, prolactin. In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2024.

Auriemma RS, Del Vecchio G, Scairati R, Pirchio R, Liccardi A, Verde N, et al. The interplay between prolactin and the reproductive system: focus on uterine pathophysiology. Front Endocrinol (Lausanne). 2020;11:594370.

Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M, et al. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med. 2013;369:2012–20.

Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med. 1999;44(12 Suppl):1075–84.

Salazar-López-Ortiz CG, Hernández-Bueno JA, González-Bárcena D, López-Gamboa M, Ortiz-Plata A, Porias-Cuéllar HL, et al. Clinical practice guideline for the diagnosis and treatment of hyperprolactinemia. Ginecol Obstet Mex. 2014;82:123–42.

Bayrak A, Saadat P, Mor E, Chong L, Paulson RJ, Sokol RZ. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril. 2005;84:181–5.